Pricing Log in Create free account

Apimeds Pharmaceuticals US, Inc. (APUS) vs Redhill Biopharma Ltd. (RDHL)

Apimeds Pharmaceuticals US, Inc. and Redhill Biopharma Ltd. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. is the larger, with a market value of $6.6M against $4.4M — 1.5× the size. Redhill Biopharma Ltd. has the higher net margin (25.2% vs 0.00%) and the higher return on invested capital (0.00% vs −16.0%). Across the 10 metrics below, Redhill Biopharma Ltd. leads on 6 and Apimeds Pharmaceuticals US, Inc. on 4.

Valuation

Metric APUS RDHL Drug Manufacturers Specialty & Generic median
P/E n/m n/m 19.25
P/S n/m 0.00 2.11
P/B 0.07 n/m 1.78
Price to free cash flow n/m n/m 16.14
EV/EBITDA n/m n/m 12.58
EV/Sales n/m 6.43 2.73
Earnings yield (905.20%) (127,222.23%) (4.38%)
Free cash flow yield (192.65%) (246,986.61%) 0.00%

Profitability

Metric APUS RDHL Drug Manufacturers Specialty & Generic median
Gross margin — 35.16% 53.94%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 25.20% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (100.13%) 0.00% (0.40%)
Return on assets (84.20%) 0.00% (3.32%)
Return on invested capital (15.96%) 0.00% 0.00%

Growth

Metric APUS RDHL Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — (61.93%) 10.01%
EPS growth (last fiscal year) (205.56%) 97.91% 49.06%
Revenue growth, 5-year CAGR — (66.15%) 6.74%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric APUS RDHL Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 0.00 0.05
Current ratio 0.51 0.34 2.31
Net debt to EBITDA 0.38 0.53 0.97

Dividend

Metric APUS RDHL Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.57%
Payout ratio — — 0.27

Size

Metric APUS RDHL Drug Manufacturers Specialty & Generic median
Market cap 6.62m 4.44m 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack